ADMA earnings call for the period ending September 30, 2020.
News & Analysis: ADMA Biologics
Shares of ADMA Biologics are on the move following the FDA's authorization of convalescent plasma for the treatment of COVID-19 patients.
Convalescent plasma holds promise for treating COVID-19, but it's still unproven.
The FDA's emergency use authorization of convalescent plasma therapy is sending these three stocks higher today.
ADMA earnings call for the period ending June 30, 2020.
ADMA earnings call for the period ending March 31, 2020.
The company's secondary stock offering was priced below its prior-day closing price.
ADMA's sneak peek at its Q4 results and an encouraging 2020 strategic update are exciting investors.
The company's attempt to relaunch Bivigam hit a wall -- again.
The tiny biopharma announced a regulatory update.